Parmax Pharma revenue halved, auditors flag MD's use of company funds
FY26 revenue fell 57% to ₹12.11 crore as auditors qualified the accounts over unauthorized mutual fund purchases in the managing director's name.
— 1 earlier story on Parmax Pharma Ltd. →What's new
- Annual revenue fell 57% to ₹12.11 crore from ₹28.20 crore in FY25.
- Net loss doubled to ₹4.16 crore from ₹2.09 crore a year earlier.
- Auditors qualified the accounts over unauthorized company funds used for mutual funds in the MD's name.
Why this matters
A qualified audit opinion for a company this small is not routine. It means the auditors found specific, material violations of the Companies Act and accounting standards that the board has not fixed. For a nano-cap with a ₹14 crore market value, these governance issues now overshadow the operational collapse.
What we're watching
- Whether the board or SEBI acts on the auditor's findings about the MD.
- The company's plan to restate accounts and address the ₹40 lakh mutual fund transaction.
- Any movement in the stock after the qualified opinion becomes public.
The full read
Parmax Pharma's fiscal year was defined by collapse. Revenue plunged 57% to ₹12.11 crore. The net loss doubled to ₹4.16 crore. But the real problem is in the auditor's report. The auditors qualified the accounts, meaning they found specific, material violations they could not reconcile. Chief among them: ₹40 lakhs of company money were used to buy mutual funds held in the managing director's name, a direct breach of Section 187 of the Companies Act. Separately, the company skipped depreciation on over ₹2 crore in plant assets and used cash-basis accounting for employee benefits, which violates accounting standards. For a company with a ₹14 crore market value, these aren't footnotes. They are the story.
Questions answered
- Why did the auditors issue a qualified opinion?
- The auditors found company funds (₹40 lakhs) were invested in mutual funds held in the managing director's name, violating Section 187 of the Companies Act. They also flagged the company's failure to record depreciation on over ₹2 crore of plant assets and its use of cash-basis accounting for employee benefits.
- How severe was the revenue decline?
- Revenue fell 57% to ₹12.11 crore in FY26 from ₹28.20 crore in the prior year. The net loss doubled to ₹4.16 crore during the same period.
- What is the specific governance violation mentioned?
- The auditors cited a contravention of Section 187 of the Companies Act, where ₹40 lakhs of company money was used to buy mutual funds registered in the managing director's personal name rather than the company's.
- What accounting irregularities were noted?
- Beyond the MD transaction, the company failed to provide depreciation on significant plant assets (over ₹2 crore) and accounts for employee benefits on a cash basis, which does not comply with standard accrual accounting requirements.
Story so far
All notes on PARMAX →- 3 Jun 2026 · 6:47 PM IST Parmax Pharma revenue halved, auditors flag MD's use of company funds
- today Parmax Pharma turns to a preferential issue after a 57% revenue crash.